{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.2","value":"136"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be calculated because only one participant was analysed.","groupId":"OG000","spread":"NA","value":"105"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 5 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"11 participants were included in the PK analysis, however MRT, could not be estimated for 1 participant due to insufficient data for elimination rate constant.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory PTCL and CTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG000","title":"PTCL and CTCL Participants: E7777 9 mcg/kg/Day"}],"paramType":"MEAN","populationDescription":"The PK analysis set was defined as a group of participants who received at least 1 dose of the study drug with at least 1 serum concentration data, and included participants who had been taken frequent blood sampling for non-compartment analysis. PK-evaluable population where data at specified time points was available.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: 0-240 minutes post-infusion; Cycle 3 and 5 Day 1: 0-120 minutes post-infusion (each Cycle length = 3 weeks)","title":"Mean Residence Time (MRT) for E7777","type":"SECONDARY","unitOfMeasure":"minutes"}